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The transcription factor PU.1 is a key player in myeloid and B-cell development as evidenced by PU.1 knockout mouse models. PU.1 is necessary for the generation and function of macrophages and granulocytes through the regulation of essential myeloid genes such as the granulocyte/macrophage colony-stimulating factor receptor (GM-CSFR), the macrophage CSF (M-CSF), the granulocyte CSF (G-CSF), CD11b, myeloperoxidase, lysozyme, neutrophil elastase, CD45, and others. [1] [2] [3] Anti-apoptotic Bcl2 proteins are frequently overexpressed during tumorigenesis 4 and three of them are expressed in myeloid cells: BCL2A1 (also designated as A1 or BFL-1) and Mcl-1 in neutrophils, whereas BCL2A1 and Bcl-x L can both be upregulated in macrophages by proinflammatory stimuli in vitro. Sevilla et al. 5 reported that PU.1 together with another Ets-family member, Ets2, transactivate the Bcl-x L promoter and increase macrophage survival. Hamasaki et al. 6 have shown that BCL2A1 deficiency accelerates spontaneous neutrophil apoptosis. Furthermore, it was reported that PU.1 is a direct target of caspase-3, an apoptosis executor, upon treatment of leukemic cells with DNA-damaging agents. 7 In line, it was found that PU.1 induces cell death in a subset of myeloma cell lines by direct activation of TRAIL. 8 Thus, Ets-family members and PU.1 directly and indirectly regulate cell death pathways.
To identify additional PU.1-regulated genes involved in cell survival, we profiled gene expression patterns of PU.1 restored 503 PU.1-null cells. We identified the anti-apoptotic BCL-2 family protein, BCL2A1, as PU.1-regulated gene. Several known PU.1 target genes, for example neutrophil collagenase, CD45, myeloperoxidase, lysozyme, and F4/80 were highly upregulated in the PU.1 rescued 503 cell line thus confirming successful restoration of PU.1 (Supplementary Table 1 ). To validate PU.1-dependent BCL2A1 upregulation, we knocked down PU.1 in NB4, HT93, and HL60 neutrophil differentiation models. To accomplish this goal, lentiviral vectors were used for stable expression of two different PU.1 short hairpin (sh) RNAs, both of which significantly reduced BCL2A1 mRNA levels in untreated control cells and upon all-trans retinoic acid (ATRA) treatment as compared with the corresponding SHC002 control cells ( To determine whether the transcription factor PU.1 binds to the BCL2A1 promoter in vivo, we performed chromatin immunoprecipitation (ChIP) assays. PU.1 was strongly associated with 4/8 putative binding sites in the BCL2A1 promoter ( Figure 2a) . As positive control for the ChIP assay, we used primers that amplify the 3 0 homology region of the À14 upstream regulatory element of PU.1.
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We next investigated whether PU.1 activates a 3.4-kb BCL2A1 promoter reporter. Cotransfection of the BCL2A1 promoter reporter together with a PU.1 expression vector resulted in a 5.9-fold activation ( Figure 2b ). As a control for promoter activation, the BCL2A1 promoter construct was cotransfected with the NF-kB subunit p65, showing high levels of activation. 11 The ChIP and reporter assays are consistent with PU.1 having a strong role in BCL2A1 regulation.
It has been reported that PU.1 and BCL2A1 expression is increased during myeloid differentiation. 12 We next investigated mRNA expression patterns and levels of both genes in 79 AML, 4 CD34 þ hematopoietic progenitor, and 6 granulocyte primary samples using quantitative RT-PCR. BCL2A1 and PU.1 mRNA levels were significantly lower in primary AML samples and in CD34 þ progenitor cells than in granulocytes (Figure 3a) . To determine the correlation between PU.1 and BCL2A1 expression in AML, we examined our cohort of 79 AML patient samples Letters to the Editor using quantitative PCR (Figure 3b) . The findings indicate a positive correlation of increased levels of PU.1 with BCL2A1 mRNA and were confirmed in a second cohort of 191 AML patients (Supplementary Figure 2) .
ATRA therapy of APL has been shown to resolve the differentiation block in APL by restoring PU.1 levels. 13 We next addressed whether ATRA treatment would restore BCL2A1 expression. Two newly diagnosed APL patients undergoing ATRA therapy were evaluated as to myeloid cell expression of PU.1 and BCL2A1 mRNA at 2 and 6 days after treatment. In the first APL patient, PU.1 and BCL2A1 mRNA were induced 8-and 7-fold at day 6, respectively. In the second patient, the genes were 8-and 18-fold elevated at day 7, respectively ( Figure 3c ). In addition, in a second study of four additional patients evaluated at diagnosis and at follow-up after undergoing ATRA therapy, PU.1 and BCL2A1 levels were increased in 3/4 and in 4/4 APL patients, respectively, after treatment (Figure 3d ). Taken together, we show that PU.1 and BCL2A1 were re-activated in APL patients, who received ATRA therapy.
Our findings show the correlation of increased PU.1 mRNA levels with that of increased BCL2A1 mRNA expression, during normal myeloid development or upon restored PU.1 expression in ATRA-treated APL cells. Moreover, the expression patterns of both PU.1 and BCL2A1 genes, low levels in AML patient samples and in CD34 þ progenitor cells as compared with granulocytes, suggests that BCL2A1 is associated with the higher levels of PU.1 found in more differentiated myeloid cells. Further, our findings of enhanced BCL2A1 expression upon differentiation of neutrophils are consistent with a report showing high BCL2A1 expression in mature neutrophils and macrophages as well as induction of BCL2A1 during myeloid development promoted by GM-CSF and G-CSF. 14 Our findings and others raise the question as to why mature neutrophils need to express high levels of an anti-apoptotic gene such as BCL2A1. Liu et al. 15 have proposed that neutrophils normally experience high levels of oxidative stress at sites of inflammation and therefore BCL2A1 might protect mature neutrophils against reactive oxidant species and help to promote their short-term survival. Moreover, Sevilla et al. 5, 16 found that enforced expression of PU.1 and Ets2 leads to prolonged macrophage survival via induction of the Bcl-xL gene, another anti-apoptotic BCL2 family member.
A report by Xia et al. 17 showed that ATRA-mediated activation of BCL2A1 in AML cell lines reduces sensitivity to chemotherapy-induced apoptosis. We next asked whether dampening PU.1 expression levels, thereby reducing BCL2A1 expression, would render AML cells more sensitive to As 2 O 3 -induced cell death. We first confirmed that ATRA pretreatment rendered NB4 SHC002 control cells less sensitive to As 2 O 3 -induced cell death. We found 10.8% less cell death in ATRApretreated NB4 SHC002 as compared with cells without ATRA pretreatment. In contrast, NB4 PU.1 knockdown cells showed Letters to the Editor significantly increased sensitivity to As 2 O 3 , 21.1 and 8.7% more cell death, respectively, upon ATRA pretreatment as compared with cells that were not pretreated with ATRA (Figure 3e ). This observed increase in cell death correlated with the lower BCL2A1 levels found in PU.1 knockdown cells. Thus, it is tempting to speculate that PU.1-dependent induction of BCL2A1 is necessary for the survival of ATRA-differentiated myeloid leukemic cells.
In conclusion, we have identified the anti-apoptotic BCL2A1 gene as a direct, transcriptional target of PU.1, which is upregulated by PU.1 induction during neutrophil differentiation. We propose that expression of the anti-apoptotic BCL2A1 gene product may control the short-term survival of mature neutrophils. In contrast, PU.1 was originally identified as a product of the Spi-1 proto-oncogene whose aberrant high expression is associated with murine erythroleukemias. 18 Therefore, we speculate that aberrant expression of PU.1 in erythroleukemia may result in elevated BCL2A1 levels that would subsequently lead to an increased survival of erythroblasts.
